168 completed, 32 unknown, 21 recruiting, 14 terminated. 65 Phase 3, 58 Phase 2, 57 Phase 4, 38 Phase 1, 33 Not applicable.
Follow Tadalafil: new trials by email Literature Review of Tadalafil trials Research Report on Tadalafil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PLEASURE (Pleasing Lovers, Efficacy, Arousal, Satisfaction, and Uptake Research on Eroxon) Eroxon®, tadalafil - Type 2 Diabetes, Type 2 Diabetes (T2DM) | Phase 4 | Suspended | University of Miami | 30 | 2026-10-01 | 2026-09-28 |
| Efficacy of Intracavernosal Xeomin With Tadalafil for Mild-Moderate Erectile Dysfunction IncobotulinumtoxinA (100 Units), Placebo, Tadalafil 20 MG - Erectile Dysfunction | Phase 2 | Not yet recruiting | Northwestern University | 30 | 2026-09-01 | 2026-08-14 |
| Effects of Tadalafil on Cognition and Cerebral Hemodynamics in Elderly Patients With Mild Cognitive Impairment Tadalafil 5 mg - Mild Cognitive Impairment (MCI) | Phase 2 | Not yet recruiting | Los Angeles Brain Science Project | 44 | 2026-09-01 | 2026-10-20 |
| Multimodal Prehabilitation and Rehabilitation for Men Undergoing Robot-Assisted Radical Prostatectomy Tadalafil 5 mg, Pelvic Floor Muscle Training (PFMT), Aerobic Exercise Program - Erectile Dysfunction Following Radical Prostatectomy, Prostate Cancer | Phase 2 | Recruiting | Surgical Outcomes Research Centre (SOuRCe) | 64 | 2026-08-31 | 2026-10-23 |
| Endothelial Markers and Tadalafil Response Tadalafil 5mg - Vasculogenic Erectile Dysfunction | Recruiting | Al-Azhar University | 120 | 2026-08-19 | 2026-08-20 | |
| Daily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction Tadalafil; Current on-demand PDE5 inhibitor, Tadalafil 5 mg - Erectile Dysfunction, Tadalafil | Phase 4 | Recruiting | Al-Azhar University | 260 | 2026-08-13 | 2026-09-01 |
| Tamsulosin Monotherapy Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Male LUTS Secondary to BPH Tamsulosin 0.4 mg + Tadalafil 2.5 mg, Tamsulosin 0.4 mg + Tadalafil 5 mg, Tamsulosin 0.4 mg - Safety, Efficacy | Not applicable | Recruiting | Ain Shams University | 90 | 2026-07-01 | 2026-07-23 |
| L-Citrulline and Tadalafil for Mild to Moderate Erectile Dysfunction L-Citrulline, Tadalafil, L-Citrulline Placebo - Erectile Dysfunction | Phase 4 | Recruiting | Beni-Suef University | 133 | 2026-06-08 | 2026-06-12 |
| Tamsulosin With or Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia Tamsulosin, Tadalafil, Tadalafil Placebo - Acute Urinary Retention, Benign Prostatic Hyperplasia | Phase 4 | Recruiting | Beni-Suef University | 320 | 2026-06-08 | 2026-06-17 |
| COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities Tadalafil, Ambrisentan, Placebo (Ambrisentan-matching) - Pulmonary Arterial Hypertension (PAH), Comorbidities | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 186 | 2026-04-28 | 2026-05-13 |
| Tadalafil 5 mg on Storage Lower Urinary Tract Symptoms After Anatomical Endoscopic Enucleation of the Prostate Tadalafil 5mg (Male), Omiga 3 - BPH (Benign Prostatic Hyperplasia) | Phase 1 | Not yet recruiting | Assiut University | 40 | 2026-03-01 | 2026-03-12 |
| Dorsal Penile Nerve Cryoneurolysis for Lifelong PE Percutaneous Dorsal Penile Nerve Cryoneurolysis, Sertraline (Oral Antidepressant), Tadalafil 5 mg - Premature Ejaculation | Not applicable | Completed | Biruni University | 117 | 2026-02-04 | 2026-10-16 |
| Phase 2 Efficacy Study of Sildenafil Products in Adult Men With Erectile Dysfunction Hezkue, Hezkue Turbo, Galotam - Erectile Dysfunction | Phase 2 | Not yet recruiting | Aspargo Labs, Inc | 200 | 2026-01-01 | 2025-11-19 |
| Safety and Efficacy of Combination of Tamsulosin 0.4 mg Plus Tadalafil 5mg Versus 2.5 mg Tamsulosin - Kidney Stone, Ureteric Stone | Not applicable | Recruiting | Ain Shams University | 140 | 2025-12-01 | 2026-05-01 |
| Daily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients Tadalafil 5 mg & Sildenafil 100mg, Sildenafil 100mg & placebo - Erectile Dysfunctions | Phase 4 | Recruiting | Mansoura University | 500 | 2025-12-01 | 2026-02-06 |
| Combination Therapy of Tadalafil 2.5mg Plus Sildenafil 25mg Versus Tadalafil 5 mg Monotherapy for Treatment of Erectile Dysfunction: A Randomized, Placebo-Controlled Double-Blinded Cross-Over Study Tadalafil 2.5 mg, Sildenafil 25 mg, Tadalafil 5 mg - Erectile Dysfunction | Phase 3 | Not yet recruiting | Assiut University | 142 | 2025-10-01 | 2025-09-24 |
| PDE5 Inhibitor for Alzheimer's Disease tadalafil, Placebo - Alzheimer Disease | Phase 2 | Not yet recruiting | Imperial College London | 244 | 2025-09-01 | 2025-09-15 |
| Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study Tadalafil 5 mg, Solifenacin 5mg - Overactive Bladder (OAB), Overactive Bladder Syndrome | Phase 4 | Recruiting | Mansoura University | 480 | 2025-09-01 | 2026-02-18 |
| Ultrasonic Enhancement Delivery of Phosphodiesterase Inhibitors Nanoparticles for Diabetic Management of the Foot Tadalafil - Diabetic Foot, Wound Healing Delayed | Not applicable | Completed | Deraya University | 1 | 2025-09-01 | 2026-08-20 |
| Solifenacin Plus Tadalafil vs Solifenacin Alone for Overactive Bladder in Females Solifenacin, Tadalafil - Overactive Bladder | Not applicable | Completed | Ain Shams University | 80 | 2025-05-15 | 2025-12-31 |
Showing 20 of 254. Sign in to see all of them.
Erectile Dysfunction (80) · Prostatic Hyperplasia (33) · Hypertension, Pulmonary (19) · Pulmonary Arterial Hypertension (17) · Lower Urinary Tract Symptoms (8) · Muscular Dystrophy, Duchenne (7) · Obesity (7) · Prostatic Neoplasms (6) · Diabetes Mellitus (5) · Premature Ejaculation (5) · Pulmonary Disease, Chronic Obstructive (5) · Squamous Cell Carcinoma of Head and Neck (5) · Diabetes Mellitus, Type 2 (4) · Hypertension (4) · Hypertrophy, Left Ventricular (4)
Eli Lilly and Company (52) · Beni-Suef University (6) · Mansoura University (6) · Actelion (5) · Ain Shams University (5) · Cedars-Sinai Medical Center (5) · Assiut University (4) · Mayo Clinic (4) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · Al-Azhar University (3) · Bayer (3) · Chong Kun Dang Pharmaceutical (3) · Dongkook Pharmaceutical Co., Ltd. (3) · Kafrelsheikh University (3) · Menoufia University (3)
United States (92) · Egypt (41) · Italy (25) · Germany (20) · Canada (17) · France (17) · South Korea (16) · United Kingdom (16) · Spain (13) · Mexico (12) · Belgium (11) · Japan (11) · Netherlands (11) · China (10) · Greece (10)
Horng H Chen, MD (3) · Abul-fotouh Ahmed (2) · Ahmed A Shokeir, professor of urology (2) · Dimitrios Hatzichristou, Prof. (2) · Elisa Giannetta, MD - Phd (2) · Gilda Cennamo (2) · Min Gul Kim, PhD (2) · Ronald G Victor, MD (2) · Ronald Victor, MD (2)
PMID 24119319, PMID 26299520, PMID 23035781, PMID 22790642, PMID 27532020, PMID 34379314, PMID 37929840, PMID 11696744, PMID 14665353, PMID 16465187, PMID 16765134, PMID 17015867, PMID 17210844, PMID 17606845, PMID 18722631, PMID 19365010, PMID 19409693, PMID 19470885, PMID 20163842, PMID 20837499, PMID 21176111, PMID 21707928, PMID 21871706, PMID 21911624, PMID 21914136, PMID 22192662, PMID 22297243, PMID 22429760, PMID 22818063, PMID 22829927, PMID 22943271, PMID 23067916, PMID 23247302, PMID 23346990, PMID 23551622, PMID 23790549, PMID 23816815, PMID 23841532, PMID 23876588, PMID 23972966, PMID 24169081, PMID 24571205, PMID 24589851, PMID 24644309, PMID 24691606, PMID 24717626, PMID 24938580, PMID 25213566, PMID 25320361, PMID 25353053
2015 (4), 2016 (2), 2009 (1), 2014 (1), 2023 (1), I01CX002543 (1), P01CA247886 (1), P01HL076611 (1), P50DE019032 (1), P50HL084946 (1), R01DK128033 (1), R01HL119155 (1), R01HL160761 (1), R21AR079755 (1), R21CA135635 (1)